Mandate

Vinge advises IRLAB Therapeutics in connection with share issues

December 13, 2019 Capital Markets and Public M&A

Vinge advises IRLAB Therapeutics in connection with a directed share issue of SEK 70 million and a rights issue of approximately SEK 145 million.

The directed share issue was subscribed for by a number of institutional and qualified investors on the basis of an accelerated book building process. The rights issue is expected to be completed during the first quarter of 2020.

IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier Growth Market, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Stephanie Stiernstedt, Stojan Arnerstål, Anna Thoms and Maria Schultzberg.

Related

Vinge advises HAKI Safety AB in connection with the acquisition of Trimtec

Trimtec is a Swedish distributor of high-tech precision equipment.
February 14, 2025

Vinge advises Industrifonden in connection with its investment in Agteria Biotech

Vinge has advised Industrifonden in connection with their participation as lead investor, together with AgriZeroNZ, in the seed financing round in Agteria Biotech AB.
February 13, 2025

Vinge advises Axcel and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB.
February 12, 2025